Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cryopreserved Cells

October 1, 2010 8:04 am | Product Releases | Comments

Lonza now offers a broad selection of cryopreserved primary human diseased airway cells including, bronchial epithelial and smooth muscle cells, and lung fibroblasts from both chronic obstructive pulmonary disease, and asthmatic donors.

TOPICS:

Cardialysis And Sticares Collaborating on Development

October 1, 2010 7:17 am | News | Comments

Cardialysis and Sticares InterACT announced that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine.

TOPICS:

AIKO Appoints New CEO

October 1, 2010 7:12 am | News | Comments

AIKO Biotechnology announced the appointment of industry veteran Jim New, Ph.D., to the newly created position of chief executive officer.

TOPICS:
Advertisement

Dyax Commercializing Ecallantide in Japan

October 1, 2010 7:09 am | News | Comments

Dyax Corp. and CMIC Co., Ltd, announced an agreement to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in Japan.

TOPICS:

Avila Begins Phase 1 Trial for Btk Drug

October 1, 2010 7:05 am | News | Comments

Avila Therapeutics, Inc. announced that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton’s tyrosine kinase.

TOPICS:

New Gene Enables Sexual Maturity

October 1, 2010 6:54 am | News | Comments

A break in the two chromosomes has given scientists a break in finding a new gene involved in puberty, Medical College of Georgia researchers report.

TOPICS:

PCR Mimic Leads Toward Supersensitive Detectors

October 1, 2010 6:50 am | News | Comments

Northwestern University researchers have taken another step towards realizing a new class of polymerase chain reaction enzyme mimics, opening the door for the development of highly sensitive chemical detection systems that go beyond nucleic acid targets.

TOPICS:

BMJ Claims Drug Companies Invent Conditions

October 1, 2010 6:46 am | News | Comments

Drug companies have not only sponsored the science of a new condition known as female sexual dysfunction, they have helped to construct it, in order to build global markets for new drugs.

TOPICS:
Advertisement

Bioethicists Fault Trial Contraception Requirement

October 1, 2010 6:43 am | News | Comments

Research ethics review committees often require all women of childbearing age who enroll in clinical trials to use contraceptives to protect against a developing fetus being exposed to potentially harmful drugs.

TOPICS:

Healthcare Reform Yields Unintended Consequences

October 1, 2010 6:36 am | by Tom Murphy | News | Comments

The new health care law could make it difficult for companies like McDonald's to continue offering limited insurance coverage to their low-wage workers.

TOPICS:

J & J And FDA Take Heat for Secret Recall

October 1, 2010 6:33 am | by Matthew Perrone | News | Comments

Johnson & Johnson executives and the Food and Drug Administration both shouldered the blame for a secret recall in which hired contractors quietly bought up defective painkillers to clear them from store shelves.

TOPICS:

Walgreen Begins Medication Disposal Program

October 1, 2010 6:31 am | by Marley Seaman | News | Comments

Walgreen Co. said it will begin selling special envelopes to shoppers to help them dispose of medications they no longer need.

TOPICS:

Merck Appealing Fraud Ruling

October 1, 2010 6:25 am | by Matthew Perrone | News | Comments

Drugmaker Merck & Co. plans to appeal a federal court verdict that a former subsidiary caused the commonwealth of Massachusetts to overpay pharmacists for a widely used asthma medication, the company said.

TOPICS:

Trileptal Costs Novartis $422.5M

October 1, 2010 6:22 am | by Kathy Matheson | News | Comments

Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced.

TOPICS:

Knockout Mouse

September 30, 2010 8:30 am | Drug Discovery & Development | Product Releases | Comments

Crescendo Biologics Limited has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The mice are believed to have the immunoglobulin heavy chain, kappa light chain, and lambda light chain loci all functionally silenced.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading